Skip to Content

'
Michael S O'Reilly, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1989 Tufts University, Boston, MA, MD, Medicine
1985 Middlebury College, Middlebury, VT, BA, Biology

Board Certifications

6/2000 American Board of Radiation Oncology

Experience/Service

Academic Appointments

Associate Professor, Department of Cancer Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2011

Institutional Committee Activities

Member, Conflict of Interest Committee, 9/2004-8/2010

Professional Memberships

American Association for Cancer Research
Member, 1991-present
American College of Radiology
Member, 1991-present
American Society of Therapeutic Radiation and Oncology
Member, 1991-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy. Am J Clin Oncol 37(1):77-80, 2/2014. e-Pub 10/2012. PMID: 23111360.
2. Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly M, Gold KA, Gomez DR. Do Angiotensin-Converting Enzyme Inhibitors Reduce the Risk of Symptomatic Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer After Definitive Radiation Therapy? Analysis of a Single-Institution Database. Int J Radiat Oncol Biol Phys. e-Pub 10/22/2013. PMID: 24161424.
3. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 9/1/2013. PMID: 23920393.
4. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-9, 6/2013. e-Pub 9/5/2012. PMID: 22950385.
5. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-9, 5/2013. e-Pub 1/8/2013. PMCID: PMC3629895.
6. Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. J Thorac Oncol 8(2):140-6, 2/2013. PMID: 23328546.
7. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 1/15/2013. e-Pub 11/30/2012. PMCID: PMC3548940.
8. Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 8(6):e67054, 2013. e-Pub 6/10/2013. PMCID: PMC3677922.
9. Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(2):e229-35, 10/1/2012. e-Pub 5/19/2012. PMCID: PMC3426644.
10. Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the VEGF Gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-50, 5/2012. e-Pub 3/8/2012. PMCID: PMC3337362.
11. Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18(6):1641-54, 3/15/2012. e-Pub 1/24/2012. PMCID: PMC3306446.
12. Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer 118(2):528-35, 1/15/2012. e-Pub 6/29/2011. PMCID: PMC3184314.
13. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 1:1-7, 2011. e-Pub 12/13/2011. PMCID: PMC3355954.
14. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5(7):940-9, 7/2010. PMID: 20512076.
15. Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10:431, 2010. e-Pub 8/16/2010. PMCID: PMC2939547.
16. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer 115:3233-42, 2009. PMID: 19472405.
17. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69(5):1534-43, 12/1/2007. e-Pub 9/24/2007. PMCID: PMC2151850.
18. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16(2):239-49, 2/2007. PMID: 17243944.
19. O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 69:S64-6, 2007. PMCID: PMC2092454.
20. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67:870-8, 2007. PMCID: PMC1976280.
21. Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6:2652-2663, 2007. e-Pub 10/2007. PMID: 17913856.
22. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483, 2007. PMID: 17308046.
23. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145-1151, 2006. PMID: 16505434.
24. Marcus K, Johnson M, Adam RM, O'Reilly MS, Donovan M, Atala A, Freeman MR, Soker S. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology 25:178-187, 2005. PMID: 16193833.
25. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 3:679-687, 2004. PMID: 15197351.
26. Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'Reilly MS, Fidler IJ, Herbst RS. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 10:8613-8619, 2004. PMID: 15623645.
27. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. PMID: 14734449.
28. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143, 2004. PMID: 14734462.
29. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9:5532-5539, 2003. PMID: 14654533.
30. Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 237:530-535, 2003. PMID: 12677150.
31. Chandra A, Liu H, Tucker SL, Liao ZX, Stevens C, Chang JY, Jeter M, O'Reilly MS, Mohan R, Cox JD, Komaki R, Guerrero T. IMRT reduces lung irradiation in distal esophageal cancer 3D CRT. Int J Radiat Oncol Biol Phys 57:S384-385, 2003.
32. Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990-1993, 2003. PMID: 12702593.
33. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 9/2002. PMID: 12228200.
34. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 120:1063-1068, 2002. PMID: 12149060.
35. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 2002. PMID: 12228199.
36. Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 61:7298-7304, 2001. PMID: 11585769.
37. Lewis VO, O'Reilly MS, Gehrmann M, Llinas M, Schaller J, Weissbach L. Inhibition of tumor growth by plasminogen-related protein-B. Anticancer Res 21:2287-2291, 2001. PMID: 11724284.
38. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207-2211, 2001. PMID: 11280788.
39. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000. PMID: 10766175.
40. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928, 1999. PMID: 10489375.
41. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568-29571, 1999. PMID: 10506224.
42. Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH. Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3:41-51, 1999. PMID: 14517443.
43. Claesson-Welsh, L, Welsh, M, Ito, N, Anand-Apte, B, Soker, S, Zetter, B, O'Reilly MS, Folkman, J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independent of the integrin-binding motif RGD. Proc Natl Acad Sci, USA 95:5579-5583, 1998.
44. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101:1055-1063, 1998. PMID: 9486976.
45. Boehm T, O'Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252:190-194, 1998. PMID: 9813168.
46. Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57:1329-1334, 1997. PMID: 9102221.
47. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997. PMID: 9389480.
48. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997. PMID: 9008168.
49. Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236:651-654, 1997. PMID: 9245707.
50. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692, 1996. PMID: 8640562.
51. Parangi, S, O'Reilly MS, Christofori, G, Holmgren, L, Grosfeld, J, Folkman, J, Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007, 1996.
52. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271:29461-29467, 1996. PMID: 8910613.
53. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-53, 1995. PMID: 7585012.
54. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995. PMID: 7538593.
55. O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30:325-329; discussion 329-330, 1995. PMID: 7738759.
56. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994. PMID: 7525077.
57. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574-84, 1994. PMID: 7521577.
58. O'Reilly MS, Rosenthal, R, Sage, EH, Smith, S, Holmgren, L, Moses, M, Shing, Y, Folkman, J. The suppression of tumor metastases by a primary tumor. Surgical Forum 44:474-476, 1993.
59. Wei X, Liao ZX, Cox JD, Allen PK, O'Reilly MS, Chang JY, Jeter MD, Guerrero TM, Bucci K, Glisson BS, Komaki R. One-cycle induction chemotherapy followed by concurrent chemoradiation therapy is associated with improved long-term survival in patients with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. Submitted.
60. Shintani T, Lewis VO, Komaki R, Raymond AK, Ryan A, Jürgensmeier JM, Herbst RS, O’Reilly MS. The impact of VEGFR and/or EGFR inhibition alone and in combination with chemotherapy in models of lung adenocarcinoma bone metastasis. Submitted.
61. Itasaka S, Komaki R, Shibuya K, Shintani T, Ryan A, Jürgensmeier JM, Herbst RS, O'Reilly MS. The influence of brain microenvironment on lung cancer growth and response to antiangiogenic therapy. Submitted.

Last updated: 6/19/2014